Reproductive Medicine Associates of New Jersey Shows 86% Delivery Rate ACCORDING TO Latest SART IVF Report
IVF Delivery Rates About 20% Higher than US Average according to Latest IVF Report from the Society for Assisted Reproductive Technology
BASKING RIDGE, N.J., May 4, 2017 – Reproductive Medicine Associates of New Jersey (RMANJ), known for their innovative and evidence-based infertility care, continues to lead the way with in vitro fertilization (IVF) success rates well above the U.S. average. Annual data released recently by Society for Assisted Reproductive Technology (SART) for the year ending December 2014 shows RMANJ with per patient success rates of 86.6% (n=723)* in women under age 35.
“Many infertility patients feel a loss of control and often struggle to find context, especially when researching their fertility issues,” offered Dr. Michael R. Drews, a founding partner and medical director based at RMANJ’s main campus in Basking Ridge, NJ. “The annual publication of clinic success rates by SART gives some control back to patients, as well as referring providers, when researching infertility care. Information is power. Processes and treatments like comprehensive chromosome screening (SelectCCS), extended embryo culture, blastocyst embryonic biopsy, and endometrial synchrony are a big part of our success rates which are well above the US average and have been for the last few years.”
“RMANJ has focused on innovation and a comprehensive, evidence-based approach for our standard of care for patients,” said Dr. Thomas Molinaro, a partner at RMANJ and leading reproductive endocrinologist at the Eatontown, NJ office. “While high success rates are important, so are healthy pregnancies and safe deliveries. At RMANJ, we’ve been able to maintain high delivery rates while performing single embryo transfers for most patients. Transferring multiple embryos may increase success rates but it comes with potential burdens and complications associated with twins and multiples.”
RMANJ’s success rates can be attributed to the quality of its IVF laboratory, as well as its use of breakthrough technologies, such as comprehensive chromosome screening (SelectCCS) – which more accurately detects healthy embryos that will lead to successful pregnancies and healthy deliveries. SelectCCS is a one-of-a-kind process that screens all 24 chromosomes at a molecular level – making it more accurate than previous testing processes that only count a handful of chromosomes. In fact, SelectCCS has demonstrated to be 98% accurate in determining embryos that have an abnormal number of chromosomes (aneuploidy).
RMANJ’s delivery rates are also impacted by the experience and dedication of its healthcare providers, individualized IVF protocols and techniques like endometrial synchrony, trophectoderm biopsy, extended embryo culture. RMANJ offers the widest range of services including: IVF, SelectCCS, pre-implantation genetic diagnosis (PGD), egg donation, gestational surrogacy, and collaborative wellness care (i.e., acupuncture, yoga, patient-to-patient networking).
As required by the Fertility Clinic Success Rate and Certification Act of 1992, reproductive endocrinologists must report IVF delivery rates to the Centers for Disease Control and Prevention (CDC) and SART, the primary organization of professionals dedicated to the practice of assisted reproductive technologies in the United States.
You can view the Final 2014 and the Preliminary 2015 SART Clinic Summary Reports at www.sart.org.
About Reproductive Medicine Associates of New Jersey
Since 1999, the leaders at RMANJ have helped bring more than 40,000 babies to loving families. In addition to serving as the Division of Reproductive Endocrinology at Rutgers Robert Wood Johnson Medical School in New Brunswick, NJ (www.reifellowship.com) and the Reproductive Endocrinology and Infertility Fellowship Program for Sidney Kimmel Medical College of Thomas Jefferson University, the practice currently has twenty-five physicians and ten locations in New Jersey: Basking Ridge, Eatontown, Englewood, Freehold, Hamilton, Morristown, Somerset, Springfield, West Orange, and its newest location in Marlton, New Jersey. For more information visit www.rmanj.com.
*SART 2014; Final live birth per patient for women under 35 include all non-banking autologous cycles and banking cycles with a thaw within 12 months of banking, representing outcomes for patients who were new to a given clinic in 2014, with births realized in 2014 and 2015. A comparison of clinic success rates may not be meaningful because a patient’s medical characteristics, treatment approaches and entrance criteria for assisted reproductive technology (ART) may vary from clinic to clinic. Visit www.sart.org to learn more.
Society for Assisted Reproductive Technology (SART) is the primary organization of professionals dedicated to the practice of assisted reproductive technologies (ART) in the United States. ART includes the practice of in vitro fertilization (IVF). The mission of our organization is to set up and help maintain the standards for ART in an effort to better serve our members and our patients. Visit www.sart.org to learn more.
Timothy Glynn, VP Program Development, RMANJ
(973) 656-2891 (direct)
Bob Friedland, Group Vice President, Kaplow Communications